medigraphic.com
Academia Mexicana de Neurología, A.C.

2019, Number 3

<< Back Next >>

Rev Mex Neuroci 2019; 20 (3)

Thyrotoxic periodic paralysis: review of the literature and case report in a high specialty Mexican university hospital

Sierra MA, Muñoz-Castañeda WR, Tolsa C, Lara AE, Medina R, Vega C

Language: Spanish
References: 36
Page: 149-154
PDF size: 131.91 Kb.


ABSTRACT

Thyrotoxic periodic paralysis (TPP) is a fatal complication of thyrotoxicosis, characterized by sudden hypokalemia, muscle paralysis and thyrotoxicosis. TPP, although it is becoming more frequent in our country, is still not diagnosed in a timely manner due to the lack of familiarity and the subtlety of the referred symptomatology. Early recognition by the first contact physician can prevent the mortality of said disease. A typical case of thyrotoxic paralysis is presented in a private Mexican university hospital and a review of the most current literature is made. We conducted a review of the literature in PubMed and EMBASE. Clinical, biochemical, diagnostic, therapeutic and prognostic characteristics were analyzed. TPP is a clinical entity that occurs rarely in the Mexican population, however it is important to be familiar with the diagnosis since the treatment is different from other periodic hypokalemic paralysis..


REFERENCES

  1. Morales-Victorino N, Guevara-Arnal L, Almeda-Valdés P. Parálisis tirotóxica: informe de un caso y revisión de la literatura. Rev Medica Sur. 2008;15(2):81-5.

  2. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: Clinical J Thyroid Res. 2014;2014:649502.

  3. Patel H, Wilches LV, Guerrero J. Thyrotoxic periodic paralysis: Diversity in America. J Emerg Med. 2014;46(6):760-2.

  4. Lam L, Nair RJ, Tingle L. Thyrotoxic periodic paralysis. Proc (Bayl Univ Med Cent). 2006;19(2):126-9.

  5. Pothiwala P, Levine SN. Analytic review: thyrotoxic periodic paralysis: a review. J Intensive Care Med. 2010;25:71.

  6. Pompeo A, Nepa A, Maddestra M, Feliziani V, Genovesi N. Thyrotoxic hypokalemic periodic paralysis: An overlooked pathology in western countries. Eur J Intern Med. 2007;18:380-90.

  7. Guerra M, Rodriguez Del Castillo A, Battaner E, Mas M. Androgens stimulate preoptic area Na+-K+ATPase activity in male rats. Neurosci Lett. 1987;78(1):97-100.

  8. Feely J. Potassium shift in thyrotoxic periodic paralysis. Postgrad Med J. 1981;57:238-9.

  9. Lee KO, Taylor EA, Oh VM, Cheah JS, Aw SE. Hyperinsulinemia in thyrotoxic hypokalemic periodic paralysis. Lancet. 1991;337(8749):1063‑4.

  10. Lin S-H. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80(1):99- 105.

  11. Salih M, van Kinschot CMJ, Peeters RP, de Herder WW, Duschek EJJ, van der Linden J, et al. Thyrotoxic periodic paralysis: an unusual presentation of hyperthyroidism. Neth J Med. 2017;75(8):315-20.

  12. Chang CC, Cheng CJ, Sung CC, Chiueh TS, Lee CH, Chau T, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol. 2013;169(5):529‑36.

  13. Goldberger ZD. Images in cardiovascular medicine. An electrocardiogram triad in thyrotoxic hypokalemic periodic paralysis. Circulation. 2007;115:e179.

  14. Hsu YJ, Lin YF, Chau T, Kuo SW, Lin SH. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci. 2003;326:128.

  15. Areta-Higuera JD, Algaba-Montes M, Oviedo-García AA. Parálisis periódica hipopotasémica. A propósito de un caso. SEMERGEN. 2014;40:4.

  16. Fisher J. Thyrotoxic periodic paralysis with ventricular fibrillation. Arch Intern Med. 1982;142:1362-4.

  17. Loh KC, Pinheiro L, Ng KS. Thyrotoxic period paralysis complicated by near-fatal ventricular arrhythmias. Singapore Med J. 2005;46:88-9.

  18. Ryzen E, Servis KL, Rude RK. Effect of intravenous epinephrine on serum magnesium and free intracellular red blood cell magnesium concentrations measured by nuclear magnetic resonance. J Am Coll Nutr. 1990;9:114-9.

  19. Tengan CH, Antunes AC, Gabbai AA, Manzano GM. The exercise test as a monitor of disease status in hypokalaemic periodic paralysis. J Neural Neurosurg Psychiatry. 2004;75:497-9.

  20. Kung AWC. Thyrotoxic periodic paralysis: A diagnostic challenge. J Clin Endocrinol Metab. 2006;91:2490-5.

  21. Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129:8.

  22. Sharma CM, Nath K, Parekh J. Reversible electrophysiological abnormalities in hypokalemic paralysis: Case report of two cases. Ann Indian Acad Neurol. 2014;17:100.

  23. Tengan CH, Antunes AC, Gabbai AA, Manzano GM. The exercise test as a monitor of disease status in hypokalaemic periodic paralysis. J Neurol Neurosurg Psychiatry. 2004;75:497.

  24. Kuntzer T, Flocard F, Vial C, Kohler A, Magistris M, Labarre-Vila A, et al. Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve. 2000;23:1089.

  25. Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM. 2001;94(3):133-9.

  26. Cesur M, Bayram F, Temel MA, Ozkaya M, Kocer A, Ertorer ME, et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clinical Endocrinology. 2008;68:143-52.

  27. Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med. 1999;159:601.

  28. Lin S-H, Chu P, Cheng C-J, Chu S-J, Hung Y-J, Lin Y-F. Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio. Crit Care Med. 2006;34(12):2984-9.

  29. Hsieh MJ, Lyu RK, Chang WN, Chang KH, Chen CM, Chang HS, et al. Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol. 2008;15(6):559-64.

  30. Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med. 2004;22(7):544-7.

  31. Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis. 2001;37(3):620.

  32. Shayne P, Hart A. Thyrotoxic periodic paralysis terminated with intravenous propranolol. Ann Emerg Med. 1994;24(4):736.

  33. Chang RY, Lang BH, Chan AC, Wong KP. Evaluating the efficacy of primary treatment for Graves’ disease complicated by thyrotoxic periodic paralysis. Int J Endocrinol. 2014;2014:949068.

  34. Akar S, Comlekci A, Birlik M, Onen F, Sari I, Gurler O, et al. Thyrotoxic periodic paralysis in a Turkish male; the recurrence of the attack after radioiodine treatment. Endocr J. 2005;52(1):149-51.

  35. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. J Thyroid Res. 2014;2014:649502.

  36. Yeung RT, Tse TF. Thyrotoxic periodic paralysis. Effect of propranolol. Am J Med. 1974;57(4):584-90.




2020     |     www.medigraphic.com